CD10 Expression in Urothelial Bladder Carcinomas: A Pilot Study
Authors:
- Sema BircanSBSema Bircan
- Ozden CandirOCOzden Candir
- Nilgun KapucuogluNKNilgun Kapucuoglu
- T. Ahmet SerelTST. Ahmet Serel
- Metin CirisMCMetin Ciris
- Nermin KarahanNKNermin Karahan
- 1 August 2006
- journal article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 77 (2) , 107-113
Abstract
Objectives: The aims of this study were to investigate the expression of CD10 in normal bladder tissue and urothelial bladder carcinomas and to clarify its association with histopathological variables. Materials and Methods: A total of 79 urothelial bladder carcinomas were selected from routine archival material. All cases were reevaluated histopathologically and graded according to the World Health Organization (WHO) 1973, WHO/ISUP 1998, and WHO 1999 systems. The TNM system was used for their pathological staging. CD10 immunohistochemical staining was performed in selected slides. Results: Tumoral cases consisted of 74 men (93.7%) and 5 women (6.3%). According to the pathological stage, 25 (31.6%), 33 (41.8%), and 21 (26.6%) cases had pTa, pT1, and pT2–3 carcinomas, respectively. 34 of 79 (43%) urothelial carcinomas and only 1 of 11 (9.1%) nontumoral cases showed positive CD10 immunostaining. It was a cytoplasmic diffuse or granular immunostaining pattern both in nontumoral and tumoral urothelia. There was no statistically significant difference between tumoral and nontumoral cases with respect to CD10 reactivity (p = 0.051), but there was a trend toward significance. In urothelial tumors, there was a significant inverse correlation between pathological stages and CD10 immunoreactivity (p = 0.036, r = –0,237). There was also a statistically significant difference between pTa and pT2–3 urothelial tumors in relation to the CD10 expression (p = 0.034). No association was detected between CD10 expression and grades according to all systems used (p > 0.05). Conclusions: According to our findings, the CD10 expression in noninvasive carcinomas showed a higher level than that in invasive carcinomas, and it is inversely correlated with the pathological stage. CD10 may play an important role in the progression of urothelial bladder carcinomas, and downregulation probably facilitates invasion, especially muscle invasion.Keywords
This publication has 23 references indexed in Scilit:
- A Panel of Immunohistochemical Stains Assists in the Distinction Between Ovarian and Renal Clear Cell CarcinomaInternational Journal of Gynecological Pathology, 2003
- CD10 Immunostaining Does Not Distinguish Endometrial Carcinoma Invading Myometrium From Carcinoma Involving AdenomyosisAmerican Journal of Surgical Pathology, 2003
- CD10 Expression in Epithelial Tissues and Tumors of the Gynecologic TractAmerican Journal of Surgical Pathology, 2003
- The Role of CD10 Staining in Distinguishing Invasive Endometrial Adenocarcinoma from Adenocarcinoma Involving AdenomyosisLaboratory Investigation, 2003
- Expression of CD10 in Malignant Müllerian Mixed Tumors and Adenosarcomas: An Immunohistochemical StudyLaboratory Investigation, 2002
- The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systemsVirchows Archiv, 2002
- Paraffin-Section Detection of CD10 in 505 Nonhematopoietic NeoplasmsAmerican Journal of Clinical Pathology, 2000
- The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary BladderAmerican Journal of Surgical Pathology, 1998
- CD10Applied Immunohistochemistry & Molecular Morphology, 1997
- A NEW TUMOR MARKER FOR BLADDER CANCERInternational Journal of Urology, 1994